Introduction to Neogen Corporation's Legal Challenges
Neogen Corporation, a prominent player in the biotechnology sector, is currently the focus of a securities fraud class action lawsuit. This legal action surrounds allegations that the company misled investors regarding its financial status and operational integrity during a critical time frame.
The Class Action Lawsuit
The lawsuit, orchestrated by a notable national shareholder rights law firm, involves investors who acquired Neogen Corporation (referred to as "Neogen" or "the Company") common stock. The Class Period is defined from January 5, 2023, through June 3, 2025. Investors have a significant deadline approaching, with the opportunity to file a lead plaintiff motion by September 16, 2025.
Details of the Allegations
The crux of the complaint alleges that Neogen engaged in making materially false and misleading statements while failing to disclose crucial adverse information about its business and operational capabilities. Specifically, the lawsuit indicates that the integration process with 3M was fraught with inefficiencies that the defendants had knowledge of, which adversely impacted key financial metrics such as goodwill impairments and margins.
Timeline of Events Impacting Neogen
One major concern surfaced on January 10, 2025, when Neogen announced a substantial reduction in its quarterly net income, reporting a staggering $461 million non-cash goodwill impairment charge in relation to its acquisition of 3M. This disclosure led to a significant stock price drop of 5.4%, closing at $12.36 per share as investors reacted to the company's struggles.
Further Financial Disclosure
The troubles for Neogen did not end there; on April 9, 2025, the company reported a 3.4% decline in quarterly revenue attributed to various integration issues. This announcement prompted further pessimism in the market, causing Neogen's stock to plummet by nearly 28.7%, closing at $5.02 per share. Investor trust continued to erode amidst continuous declines and unfulfilled projections.
Current Status and Next Steps for Investors
As of June 4, 2025, Neogen maintained that its financial results would only marginally meet its earlier projections, noting potential negative impacts to EBITDA margins due to rising inventory write-offs. Another stock drop followed, closing at $4.96 per share—an additional blow for investors already seeking clarity and accountability.
Participating in the Class Action
Investors who purchased or otherwise acquired Neogen valued stocks during the specified Class Period are encouraged to consider filing a motion to join the class action suit as lead plaintiff. This step not only allows for potential recovery of losses but also presents a crucial opportunity for accountability.
Contact for Further Information
Investors interested in participating or learning more can reach out for additional details. Charles Linehan, Esq., from Glancy Prongay & Murray LLP is available for inquiries. You can find him at:
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Frequently Asked Questions
What is the nature of the lawsuit against Neogen Corporation?
The lawsuit alleges securities fraud, claiming the company made misleading statements about its financial health and business operations.
What is the deadline for investors to act?
Investors must file a lead plaintiff motion by September 16, 2025.
How has Neogen's stock responded to news?
Neogen's stock has experienced notable drops, including a 5.4% decrease and a decline of 28.7% over recent disclosures.
Who can participate in this class action?
Investors who purchased Neogen common stock during the Class Period may participate in the class action.
How can I learn more about my rights regarding this lawsuit?
Interested parties should contact Glancy Prongay & Murray LLP for detailed information on participation and rights.
